Metagenomi Therapeutics
54 hedge funds and large institutions have $49.6M invested in Metagenomi Therapeutics in 2024 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 11 closing their positions.
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
8% more funds holding
Funds holding: 50 → 54 (+4)
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
3% less ownership
Funds ownership: 35.53% → 32.54% (-3%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
65% less capital invested
Capital invested by funds: $140M → $49.6M (-$90.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.1M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$1.73M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$532K |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$418K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$303K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Principal Financial Group
Des Moines,
Iowa
|
-$3.7M |
| 2 |
Millennium Management
New York
|
-$2.98M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.87M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.83M |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$1.32M |
MGX Hedge Fund Activity: Q2 2024 in Review
54 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q2 2024, worth a combined $49.6M — down 65% from $140M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new MGX positions and 11 closed out — a net gain of 4 holders — while 15 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $2.1M. The largest seller was Principal Financial Group, exiting entirely with an estimated $3.7M sold.
- 54 institutional investors held Metagenomi Therapeutics (MGX) as of Q2 2024, up from 50 in Q1 2024.
- Funds reported $49.6M of Metagenomi Therapeutics stock for Q2 2024, down 65% quarter-over-quarter.
- 15 funds opened new Metagenomi Therapeutics positions in Q2 2024 and 11 closed out, a net change of +4 holders.
- The largest Metagenomi Therapeutics buyer in Q2 2024 was BlackRock, an estimated $2.1M added.
- The largest Metagenomi Therapeutics seller in Q2 2024 was Principal Financial Group, an estimated $3.7M sold.
Based on aggregated 13F filings for Q2 2024.